PMID- 29783074
OWN - NLM
STAT- MEDLINE
DCOM- 20180613
LR  - 20180613
IS  - 1879-0038 (Electronic)
IS  - 0378-1119 (Linking)
VI  - 668
DP  - 2018 Aug 20
TI  - FSH receptor binding inhibitor restrains follicular development and possibly 
      attenuates carcinogenesis of ovarian cancer through down-regulating expression 
      levels of FSHR and ERbeta in normal ovarian tissues.
PG  - 174-181
LID - S0378-1119(18)30563-8 [pii]
LID - 10.1016/j.gene.2018.05.068 [doi]
AB  - OBJECTIVES: The current study aimed to investigate FSH receptor binding inhibitor 
      (FRBI) effects in the expressions of FSH receptor (FSHR) and estrogen 
      receptor-beta (ERbeta) in the mice ovaries at the gene and protein levels, also to 
      find the potential efficacy of FRBI on suppressing ovarian cancer through 
      down-regulating over-expression of FSHR and ERbeta in the normal ovarian tissues. 
      METHODS: 180 female mice were randomized into six groups (n = 30). Mice of 
      FRBI-1, FRBI-2 and FRBI-3, FRBI-4 were intramuscularly injected with FRBI of 10, 
      20, 30 and 40 mg/kg, respectively, for five consecutive days. The qPCR and 
      Western blotting were used to determine expression levels of FSHR and ERbeta mRNAs 
      and proteins in mouse ovaries. RESULTS: The ovarian cortex thickness (OCT) of the 
      FRBI-4 group were less than that FSH group on day 30 (P < 0.05). The numbers of 
      secondary follicles (SF) and the maximum transverse diameters (MTD) of secondary 
      follicles of FRBI-3 and FRBI-4 groups were decreased as compared to FSH group 
      (P < 0.05 or P < 0.01) by 24.11% and 27.47% on day 20 based on the control group 
      (CG) levels. On day 15, the reductions of FSHR mRNA levels in FRBI-2, FRBI-3 and 
      FRBI-4 were 27.78%, 29.37% and 43.65% (P < 0.05 or P < 0.01), respectively in 
      comparison with CG. ERbeta and FSHR protein levels of FRBI-treated mice were 
      gradually decreased as compared to and CG and FSH group. ERbeta protein level of 
      FRBI-4 was less than that of CG on day 20 (P < 0.05). On days 15 and 20, 
      estradiol (E(2)) concentrations of FRBI-2, FRBI-3 and FRBI-4 groups were lower 
      than those of the CG and FSH group (P < 0.05 or P < 0.01). CONCLUSIONS: FRBI 
      could reduce OCT and follicle numbers. A high dose of FRBI (30 mg/kg to 40 mg/kg) 
      could suppress ovarian and follicular development, and attenuate expression 
      levels of ERbeta and FSHR mRNAs and proteins in the ovaries, additionally inhibit 
      E(2) production. Therefore, FRBI will possibly be utilized to restrain the 
      carcinogenesis of ovarian cancer by down-regulating overexpression of FSHR and 
      ERbeta in the ovaries.
CI  - Copyright (c) 2018 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Zhuandi, Gong
AU  - Zhuandi G
AD  - Hospital of Medicine College, Northwest Minzu University, China.
FAU - Tuanjie, Che
AU  - Tuanjie C
AD  - Key Laboratory of Functional Genomic and Molecular Diagnosis of Gansu Province, 
      China.
FAU - Luju, Lai
AU  - Luju L
AD  - Life Science and Engineering College, Northwest Minzu University, China.
FAU - Abdiryim, Ayimuguli
AU  - Abdiryim A
AD  - Life Science and Engineering College, Northwest Minzu University, China.
FAU - Yingying, Deng
AU  - Yingying D
AD  - Research Center of Animal Cell Engineering and Technology of Gansu Province, 
      Northwest Minzu University, China.
FAU - Haoqin, Liang
AU  - Haoqin L
AD  - Life Science and Engineering College, Northwest Minzu University, China.
FAU - Suocheng, Wei
AU  - Suocheng W
AD  - Life Science and Engineering College, Northwest Minzu University, China; Research 
      Center of Animal Cell Engineering and Technology of Gansu Province, Northwest 
      Minzu University, China. Electronic address: weisc668@163.com.
FAU - Li, Ding
AU  - Li D
AD  - Technology Center of Hunan Entry-exit Inspection and Quarantine Bureau, China. 
      Electronic address: dingli0824@126.com.
LA  - eng
PT  - Journal Article
DEP - 20180518
PL  - Netherlands
TA  - Gene
JT  - Gene
JID - 7706761
RN  - 0 (Estrogen Receptor beta)
RN  - 0 (Peptides)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, FSH)
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Animals
MH  - Carcinogenesis
MH  - Down-Regulation
MH  - Estradiol/blood
MH  - Estrogen Receptor beta/*metabolism
MH  - Female
MH  - Gene Expression
MH  - Mice
MH  - Ovarian Follicle/anatomy & histology/drug effects
MH  - Ovarian Neoplasms/etiology
MH  - Ovary/anatomy & histology/drug effects/*metabolism
MH  - Peptides/pharmacology
MH  - RNA, Messenger/metabolism
MH  - Receptors, FSH/genetics/*metabolism
OTO - NOTNLM
OT  - Estrogen receptor
OT  - FSH receptor binding inhibitor
OT  - Follicle stimulating hormone
OT  - Mice
OT  - Ovarian cancer
OT  - Overexpression
EDAT- 2018/05/22 06:00
MHDA- 2018/06/14 06:00
CRDT- 2018/05/22 06:00
PHST- 2018/03/09 00:00 [received]
PHST- 2018/05/08 00:00 [revised]
PHST- 2018/05/17 00:00 [accepted]
PHST- 2018/05/22 06:00 [pubmed]
PHST- 2018/06/14 06:00 [medline]
PHST- 2018/05/22 06:00 [entrez]
AID - S0378-1119(18)30563-8 [pii]
AID - 10.1016/j.gene.2018.05.068 [doi]
PST - ppublish
SO  - Gene. 2018 Aug 20;668:174-181. doi: 10.1016/j.gene.2018.05.068. Epub 2018 May 18.